

This PDF is a selection from a published volume from the National Bureau of Economic Research

Volume Title: Measuring and Modeling Health Care Costs

Volume Author/Editor: Ana Aizcorbe, Colin Baker, Ernst R. Berndt, and David M. Cutler, editors

Volume Publisher: University of Chicago Press

Volume ISBNs: 978-0-226-53085-7 (cloth); 978-0-226-53099-4 (e-ISBN)

Volume URL: <http://www.nber.org/books/aizc13-1>

Conference Date: October 18-19, 2013

Publication Date: February 2018

Chapter Title: Indexes

Chapter Author(s):

Chapter URL: <http://www.nber.org/chapters/c14340>

Chapter pages in book: (p. 505 – 522)

Contributors

Jean M. Abraham
Division of Health Policy and
Management
University of Minnesota
420 Delaware Street SE, MMC 729
Minneapolis, MN 55455

Murray L. Aitken
IMS Institute for Healthcare
Informatics
901 Main Avenue, Suite 612
Norwalk, CT 06851

Ana Aizcorbe
Bureau of Economic Analysis
4600 Silver Hill Road
Suitland, MD 20746

Colin Baker
US Department of Health and Human
Services
200 Independence Avenue SW
Washington, DC 20201

Laurence C. Baker
Department of Health Research &
Policy
HRP Redwood Building
Stanford University
Stanford, CA 94305-5405

Didem Bernard
Agency for Healthcare Research and
Quality
Center for Financing, Access, and Cost
Trends
540 Gaither Road
Rockville, MD 20850

Ernst R. Berndt
MIT Sloan School of Management
100 Main Street, E62-518
Cambridge, MA 02142

Barry Bosworth
The Brookings Institution
1775 Massachusetts Avenue
Washington, DC 20036

Ralph Bradley
Division of Price and Index Number
Research
Bureau of Labor Statistics
2 Massachusetts Avenue, NE
Washington, DC 20212

M. Kate Bundorf
Health Research and Policy
Stanford University
HRP T108
Stanford, CA 94305-5405

Brian Chansky
Bureau of Labor Statistics
Division of Industry Productivity
Studies
2 Massachusetts Avenue, NE
Washington, DC 20212

Michael E. Chernew
Harvard Medical School
Department of Health Care Policy
180 Longwood Avenue
Boston, MA 02115

Iain M. Cockburn
School of Management
Boston University
595 Commonwealth Avenue
Boston, MA 02215

Rena M. Conti
University of Chicago
Department of Pediatrics
Section of Hematology/Oncology
5812 S. Ellis Street
Chicago, IL 60637

David M. Cutler
Department of Economics
Harvard University
1875 Cambridge Street
Cambridge, MA 02138

Abe Dunn
Bureau of Economic Analysis
4600 Silver Hill Road
Suitland, MD 20746

Roger Feldman
Division of Health Policy and
Management
University of Minnesota
420 Delaware Street SE, MMC 729
Minneapolis, MN 55455

Armando Franco
Department of Economics
University of California, Berkeley
Berkeley, CA 94720

Richard Frank
Department of Health Care Policy
Harvard Medical School
180 Longwood Avenue
Boston, MA 02115

Corby Garner
Bureau of Labor Statistics
2 Massachusetts Avenue, NE
Washington, DC 20212

Kaushik Ghosh
National Bureau of Economic
Research
1050 Massachusetts Avenue
Cambridge, MA 02138

Jacob Glazer
Department of Economics
Warwick University
Coventry CV4 7AL United Kingdom
and Collier School of Management
Tel Aviv University
Ramat Aviv, Tel Aviv, Israel

Dana P. Goldman
Schaeffer Center for Health Policy and
Economics
University of Southern California
635 Downey Way
Los Angeles, CA 90089-3333

Anne E. Hall
Office of Microeconomic Analysis
US Treasury Department
1500 Pennsylvania Avenue, NW
Washington, DC 20220

Tina Highfill
Bureau of Economic Analysis
4600 Silver Hill Road
Suitland, MD 20746

Pinar Karaca-Mandic
Division of Health Policy and
Management
University of Minnesota
420 Delaware Street SE, MMC 729
Minneapolis, MN 55455

Michael Kleinrock
QuintilesIMS Institute
QuintilesIMS
One IMS Drive
Plymouth Meeting, PA 19462

J. Steven Landefeld
Economics Department
US Naval Academy
589 McNair Road
Annapolis, MD 21402-5030

Adam Leive
Frank Batten School of Leadership
and Public Policy
University of Virginia
235 McCormick Road
Charlottesville, VA 22904

Frank R. Lichtenberg
Graduate School of Business
Columbia University
3022 Broadway
New York, NY 10027

Eli Liebman
Bureau of Economic Analysis
4600 Silver Hill Road
Suitland, MD 20746

Matilde Mas
Faculty of Economics
Universitat de València
Edificio Departamental Oriental
Avda. Tarongers, s/n.
46022 Valencia, Spain

Daniel McFadden
University of California, Berkeley
Department of Economics
508-1 Evans Hall #3880
Berkeley, CA 94720-3880

Thomas G. McGuire
Department of Health Care Policy
Harvard Medical School
180 Longwood Avenue
Boston, MA 02115

Yuriy Pylypchuk
Office of the National Coordinator for
Health Information Technology
330 C Street, SW
Washington, DC 20024

Ronjoy Raichoudhary
Bureau of Labor Statistics
2 Massachusetts Avenue, NE
Washington, DC 20212

Allison B. Rosen
Department of Quantitative Health
Sciences
University of Massachusetts Medical
School
368 Plantation Street, AS9-1083
Worcester, MA 01605

Anne Royalty
Department of Economics
Indiana University Purdue University
Indianapolis
425 University Boulevard
Indianapolis, IN 46202

Paul Schreyer
Organisation for Economic Co-
Operation and Development
2, rue André Pascal
75775 Paris Cedex 16 France

Thomas Selden
Agency for Healthcare Research and
Quality
Center for Financing, Access, and Cost
Trends
540 Gaither Road
Rockville, MD 20850

Bradley T. Shapiro
University of Chicago Booth School of
Business
5807 South Woodlawn Avenue
Chicago, IL 60637

Adam Hale Shapiro
Economic Research Department
Federal Reserve Bank of San Francisco
101 Market Street
San Francisco, CA 94105

Julie Shi
School of Economics
Peking University
5 Yiheyuan Road
Haidian District
Beijing 100871 China

Christopher Stomberg
Bates White Economic Consulting
1300 Eye Street NW
Suite 600
Washington, DC 20005

Kosali Simon
School of Public and Environmental
Affairs
Indiana University
1315 East Tenth Street
Bloomington, IN 47405-1701

Author Index

- Abaluck, J., 385n10
 Abraham, J. M., 421, 422, 424, 426n8, 427, 428, 428n10, 442, 443, 444
 Abraham, K. G., 27
 Adams, J. D., 477
 Aitken, M. L., 244n1, 244n4, 247n13, 250n14, 253, 274, 276, 284, 285n1, 306
 Aizcorbe, A., 82, 85, 99n21, 111, 115, 118, 119, 157, 174, 181, 201, 391
 Akerlof, G. A., 380n3
 Akobundu, E., 201
 Akscin, J., 281
 Allison, E., 461
 Alpert, A., 245n10, 280, 283
 Amemiya, T., 231
 Antwi, Y. A., 352
 Appelt, S., 244n7, 245n9
 Atkinson, A., 27, 37, 44
 Auerbach, D. I., 357

 Baker, C., 236, 236n20
 Baker, L. C., 82, 84, 95, 98, 352
 Balk, B., 35n7
 Barr, T. R., 280, 281
 Basu, A., 71n5, 186, 188, 202
 Berenson, R. A., 351, 352
 Berk, A., 174, 177
 Bernard, D. M., 462n3, 463, 471
 Berndt, E. R., 27, 31, 32, 32n5, 36, 81, 115, 244n1, 244n2, 244n4, 244n7, 245n9, 246n11, 247n13, 250n14, 253, 253n16, 256n19, 274, 276, 285, 285n1, 306, 307, 323, 328n7
 Berry, S., 282, 283, 306
 Bhat, S., 336n27
 Bhattacharya, J., 212, 214n5, 214n7, 217n12, 218n15, 462n3
 Bloom, B. S., 174
 Blumberg, L., 443
 Bond, A. M., 351
 Bosworth, B. P., 27
 Boudreaux, M., 421, 422
 Bradley, R., 174, 201, 218n15
 Branstetter, L. G., 244n7, 245n9
 Bresnahan, T. F., 282, 284
 Brill, A., 244n6, 251
 Buchanan, J., 76
 Buchmueller, T., 443
 Buerhaus, P. I., 357
 Bundorf, M. Kate, 82, 84, 95, 98, 214n5, 214n7, 382, 384n8, 386
 Buntin, M. B., 116, 186, 188, 202
 Burton, T., 59

 Cantor, J. C., 422
 Carlin, C., 386
 Carter, G., 382
 Casalino, L. P., 353, 353n1, 354
 Castelli, A., 47
 Catron, B., 167
 Caves, R. E., 244n2, 244n4, 253n16, 274, 283, 284, 285, 307

- Cawley, J., 211, 212, 213, 214, 219, 220, 234, 235
Chandra, A., 66
Chang, L. V., 244n6, 252
Chatterjee, C., 244n7, 245n9
Chernew, M., 81
Claxton, G., 447
Clemens, J., 280
Cockburn, I. M., 244n2, 250n14, 253n16, 284, 306
Cohen, A. J., 174, 177, 194
Cohen, S. B., 462
Conti, R. M., 274, 277, 281, 285, 290, 306, 323, 328n7
Cook, A., 244n2, 244n3, 250n14, 253n16
Cooper, B. S., 174, 194
Coutts, E., 463
Cox, C., 447
Crosson, F. J., 352
Cuckler, G. A., 459
Cuellar, A. E., 352
Cullen, M., 380n2, 382, 383, 384, 384n6
Cutler, D. M., 27, 84, 105, 115, 158, 173, 174, 181, 201, 212, 213, 215, 244n1, 244n4, 250n14, 253, 274, 306, 380n3, 396n25, 475
Cylus, J., 158

Dafny, L., 352, 386, 426n8
Dahlof, B., 56
Davidoff, A., 443
Deaton, A., 475
DeLeire, T., 424
Devlin, J. W., 336n27
Dickensheets, B., 158
Diewert, W. E., 33, 35n7
DiNardo, J., 443
Dominiak, L., 82, 85, 174
Dorfman, R., 331n11
Douglas, J., 149n10
Dow, W. H., 220n16
Dragone, D., 213, 215
Druss, B. G., 174, 180
Duan, N., 116, 194
Duarte, F., 280, 283
Duchnovny, N., 236, 236n20
Duggan, M., 245, 285n1
Dunn, A., 82, 85, 86n2, 87, 91n10, 92n11, 92n12, 94n14, 95, 99n21, 101n24, 101n25, 111, 115, 119, 174, 181, 201, 352
Earle, C., 281, 285, 306
Einav, L., 380n2, 382, 383, 384, 384n6, 386
Elixhauser, A., 192
Ellis, R. P., 394n22
Ellison, G., 244n2, 253n16
Ellison, S. F., 244n2, 250n14, 253n16, 284, 285, 306
Evenson, R. E., 477

Feenberg, D., 463
Feldman, R., 443
Feldstein, M., 461
Fiebelkorn, I. C., 211
Finkelstein, A., 380n2, 382, 383, 384, 384n6, 386
Finkelstein, E. A., 118, 194, 211
Fixler, D., 167
Florence, C. S., 99n21, 174, 180, 194, 211, 235
Fox, E. R., 335n20, 336n23, 336n26
Frank, R. G., 244n2, 244n3, 274, 279, 284, 285, 289, 306, 307
Franklin, S., 56
Friedman, B., 155
Fuchs, V. R., 476n1

Galactionova, K., 174
Galiani, S., 486n13
Gatesman, M., 278
Gaynor, M. S., 306, 351, 352
Gertler, P. J., 352, 486n13
Geruso, M., 386
Ginsburg, M., 167
Ginsburg, P. B., 352
Glaeser, E. M., 212, 213, 215
Glazer, J., 380n3, 382, 384n8
Goerlich, F., 42
Gold, M. R., 37
Goldberg, P., 278
Goldman, D., 62, 76
Gornick, M., 75
Gottlieb, J. D., 280
Grabowski, H. G., 244n2, 244n5, 244n6, 244n7, 250n14, 253n16, 274, 282, 283, 284, 285, 306, 307
Graham, J. R., 323
Graven, P., 443
Gray, B. M., 461
Griliches, Z., 244n2, 250n14, 253n16, 284, 306
Grossman, J. M., 351

- Growlec, J., 489n15
 Gruber, J., 385n10
 Gu, W., 42

 Hall, A. E., 111, 118, 124n1, 201
 Hall, H., 56
 Hall, J. M., 446
 Hall, M. A., 447n14
 Hamilton, B., 75
 Handel, B., 386
 Haninger, K., 333
 Haught, R., 461
 Hellerstein, J. K., 245n10
 Helms, R. B., 461
 Hemphill, C. S., 244n5, 244n7
 Hendel, I., 386
 Henderson, R., 145
 Higgins, M. J., 244n7, 245n9
 Highfill, T., 111, 118, 124n1, 201
 Hill, T. P., 27, 30
 Ho, K., 386
 Hodgson, T. A., 174, 177, 194
 Hoerger, T. H., 118, 194
 Hoffman, C., 174, 177
 Hogan, P., 461
 Honeycutt, A. A., 201
 Horowitz, L. A., 174
 Howard, D. H., 174
 Huckfeldt, C. R., 285, 307
 Huckman, R. S., 244n6, 256n18, 306
 Hurwitz, M. A., 244n2, 244n4, 253n16, 274, 283, 284, 285, 307
 Huskamp, H. A., 253n16
 Hüttl, A., 42

 Iizuka, T., 276, 282, 283, 287, 289, 305

 Jacobson, M., 280, 281, 283, 285, 306
 Jessup, A., 333
 Jones, A. M., 116
 Jordan, W. M., 280
 Jorgenson, D. W., 28, 29
 Joski, P., 99n21, 174, 180, 194, 211, 235
 Joyce, G., 62

 Karaca-Mandic, P., 421, 422, 424, 426n8, 427, 428, 428n10, 442, 443, 444
 Keeler, E., 382
 Kelton, C. M., 244n6, 252
 Kerwin, J., 184
 Kessler, D. P., 364

 Ketcham, J. D., 352
 Kislev, Y., 477
 Klerman, J. A., 422
 Knittel, P. J., 285, 307
 Kocher, R., 351
 Koechlin, F., 30, 43, 46, 46n2
 Koehler, M. A., 333
 Kolstad, J. T., 306, 384n6
 Koopmanschap, M. A., 174
 Kopstein, A. N., 174, 177
 Kornfield, R., 307
 Kowalski, A., 384n6
 Kreling, D. H., 244n6, 252
 Kyle, M. K., 244n2, 244n5, 274, 282, 285, 307

 Lakdawalla, D., 462n3
 Landefeld, J. S., 28
 Lane, S. G., 158n24
 Leibowitz, A., 76
 Levin, J. D., 380, 384n8, 386, 417
 Levitt, L., 447
 Li, Y., 56
 Lichtenberg, F. R., 476, 489, 495n20
 Liebman, E., 82, 85, 86n2, 95, 99n21, 101n24, 101n25, 174, 181, 201, 309, 323, 330, 330n9, 333
 Liehaber, A., 351
 Lincoln, G., 396n25
 Ling, D., 274, 285, 307
 Lipscomb, J., 201
 Liu, X., 446
 Lleras-Muney, A., 475
 Long, G., 244n2, 244n6, 307
 Long, S., 443
 Lorenzoni, L., 30, 43, 46, 46n2
 Lucarelli, C., 386
 Lustig, J., 386

 Mach, A., 422
 MacIsaac, D., 352
 Mackie, C., 27
 MaCurdy, T., 184
 Maddala, G. S., 219
 Mahoney, N., 382, 384n8, 386
 Malin, J. L., 281
 Maness, R., 244n2, 244n3, 274, 283, 284, 285, 287, 305
 Mankiw, N. G., 282, 306
 Manning, W. G., 116, 186, 188, 202
 Marquis, M. S., 443

- Martin, A. B., 459
Martin, J. B., 475
Mas, M., 29
Matchar, D., 61
McClellan, M. B., 364, 462
McCue, M. J., 446, 447n14
McGlynn, E. A., 184
McGuire, T. G., 380n3, 382, 384n8, 393n20
McWilliams, J. M., 352, 356
Meeker, D., 76
Melnick, G. A., 352
Meyerhoefer, C., 211, 212, 213, 214, 219, 220, 234, 235
Miller, G. E., 461, 471
Moeller, J. F., 460
Moffitt, R., 462n3
Monheit, A., 424, 456
Morin, S., 42
Mortimer, R., 244n2, 244n6, 307
Moses, H., 475
Mullahy, J., 116, 186, 202
Murphy, B., 167
Mushkin, S. J., 174, 177

Nabel, E. G., 475
Nakamura, A., 35n7
Nestoriak, N., 82, 99n21, 111, 115, 119, 157, 174, 181, 201
Neumann, P. J., 280
Newey, W. K., 212
Newhouse, J. P., 81, 250n14, 256n19, 276, 281, 285, 306, 382, 400n27
Nichols, L., 443
Norton, E. C., 220n16

Ogden, L. L., 174
O'Hara, B., 422
Olin, G., 85, 121, 391
Olson, L. M., 244n7, 245n9, 260n23
O'Malley, A. S., 351

Pack, S., 174, 181, 201
Palmer, L., 192
Panattoni, L. E., 244n7, 304
Paringer, L., 174, 177
Park, R., 116
Pauly, M. V., 218n15
Pelnar, G. J., 354
Pérez, F., 29
Pham, H. H., 355
Phelps, C., 424, 444
Pindyck, R. S., 281

Pope, G. C., 355, 394
Powell, J. L., 212
Prince, J., 386
Pylypchuk, Y., 463

Reber, S., 380n3
Regan, T. L., 244n3, 253n16
Reiffen, D. E., 244n2, 245n9, 258n20, 274, 282, 284, 285, 305
Reiss, P., 282, 283, 284, 306
Rennane, S., 470
Retus, B. A., 174, 181, 201
Rice, D. P., 174, 176, 177, 194
Ridley, D. B., 309, 323, 330, 330n9, 333
Rittmueller, L., 174, 181, 201
Roberts, R., 336n27
Roehrig, C., 82, 85, 98, 98n20, 99n21, 103n28, 174, 180, 181
Romer, P., 476
Rosen, A. B., 27, 92n11, 158, 174, 184, 201
Rothschild, M., 380n3
Rousseau, D., 82, 85, 98, 98n20, 99n21, 103n28, 174, 180, 181
Royalty, A. B., 82, 84, 95, 98, 424
Rubinfeld, D. L., 282
Ruhm, C. J., 212, 215
Russo, C. A., 155

Safar, M., 56
Saha, A., 244n2
Sahni, N. R., 173, 351
Salkever, D. S., 244n2, 244n3, 274, 284, 285, 289, 306, 307
Sampat, B. N., 244n5, 244n7, 476
Savorelli, L., 213, 215
Schargrodsky, E., 486n13
Scherer, F. M., 306
Schneider, J. E., 352
Schone, B. S., 424, 443
Schreyer, P., 27, 29, 30, 32, 33, 36, 37, 42, 43, 46, 46n2
Schumacher, I., 489n15
Schwartz, L. M., 484
Scitovsky, A. A., 174, 177
Scott Morton, F. M., 244n2, 244n6, 274, 276, 277, 282, 285, 285n1, 287, 289, 305
Selden, T. M., 460, 461, 462, 462n3, 463, 471
Senese, J. L., 280, 281
Shapiro, A. H., 82, 85, 86n2, 94n14, 95, 99n21, 101n24, 101n25, 174, 181, 201, 375
Shapiro, I., 115

- Shapiro, J. M., 212, 213, 215
 Shapiro, M. D., 115
 Sheils, J., 461
 Shen, Y. C., 352
 Simon, K., 386, 426n8, 428, 442, 443
 Sing, M., 391, 462, 471
 Sipahi, I., 58, 58n2
 Skinner, J., 462
 Sloan, F. A., 471
 Smedby, B., 46n2
 Smith, A., 247n13
 Smith, S., 174, 181, 201
 Smith, T., 278
 Song, X., 174, 201
 Sood, N., 212, 214n7, 217n12, 218n15
 Spinnewijn, J., 385n9
 Staiger, D. O., 66, 357
 Starr, M., 82, 85, 174
 Steiner, C., 192
 Steiner, P. O., 331n11
 Steuerle, C. E., 470
 Stiglitz, J., 380n3
 Stranges, E., 155
 Strauss, M., 56
 Stromberg, C., 309
 Sung, H. Y., 174, 177

 Theobald, N., 184
 Thorpe, K. E., 99n21, 174, 180, 194, 211, 235
 Tirole, J., 282
 Todd, P., 57
 Towle, E. L., 280, 281
 Town, R. J., 351, 386
 Triplett, J. E., 27, 35n9, 36, 36n10, 37, 47, 154
 Trish, E., 391n15
 Trogdon, J., 116, 194

 Uriel, E., 29

 Van de Ven, W. P. M. M., 394n22
 Vanoli, A., 33n6

 Varela, M., 386
 Varmus, H., 484
 Vella, F., 213
 Vernon, J. M., 244n2, 250n14, 253n16, 274, 282, 283, 284, 285, 306
 Vijan, S., 27
 Vogt, W., 306, 352

 Wang, G., 211
 Wang, J., 56, 471
 Wang, X., 244n7
 Ward, M. E., 244n2, 245n9, 258n20
 Ward, M. M., 201
 Ward, M. R., 274, 282, 284, 285, 305
 Wasylenko, M. J., 462
 Welch, C. A., 202
 Welch, H. G., 484
 Welch, W. P., 352, 355, 356, 357
 Wendling, B. W., 244n7, 245n9, 260n23
 Whinston, M. D., 244n2, 244n4, 253n16, 274, 282, 283, 284, 285, 306, 307, 386
 Whitmire, B., 174, 181, 201
 Wiggins, S. N., 244n2, 244n3, 274, 283, 284, 285, 287, 305
 Wilcox, D. W., 115
 Wilson, D., 278
 Wolfe, B., 462n3
 Woloshin, S., 484
 Wolpin, K., 57
 Woodcock, J., 278, 323, 328
 Wosinska, M., 244n6, 256n18, 278, 323, 328
 Wu, V. Y., 352

 Yabroff, K. R., 201
 Yun, K.-Y., 28
 Yurukoglu, A., 308, 323, 330, 330n9, 333

 Zaslavsky, A. M., 116, 186, 188, 202
 Zeckhauser, R., 396n25
 Zhang, H. H., 471
 Zhu, J. M., 393n21
 Zissimopoulos, J., 62
 Zuvekas, S., 85, 121, 391

Subject Index

Note: Page numbers followed by “f” or “t” refer to figures or tables, respectively.

- Abbreviated New Drug Applications (ANDAs), 275–76; information and regulatory timing of, 277–78; price and use models of, theoretical considerations, 284–86; theoretical considerations and empirical findings for entry models of, 281–83
- ACA. *See* Affordable Care Act (ACA) of 2010
- accounting, health, 1
- ACE (angiotensin-converting enzyme) inhibitors, 58
- active pharmaceutical ingredients (API), 276
- adverse selection: efficiency costs of, 382–84, 383f; “Einav-Finkelstein” form of, 380; risk adjustment and, 379–80; risk adjustment to fix, 386–90
- Affordable Care Act (ACA) of 2010, 17–20, 379, 382, 386, 419–21; plan levels in, 382, 393
- AHA (American Hospital Association) Annual Survey, 150, 150n15, 165
- all-encounter approach, to COI allocation, 176, 194; literature review using, 180–81, 182–83t
- Ambien CR, 266–67
- American Hospital Association (AHA) Annual Survey, 150, 150n15, 165
- ANDAs. *See* Abbreviated New Drug Applications (ANDAs)
- angiotensin-converting enzyme (ACE) inhibitors, 58
- angiotensin II receptor blockers (ARBs), 4, 56–57, 58; cancer rates and propensity to prescribe, 66–69, 67f, 72–73, 73t; contamination bias and analysis of, 60–63; death rates and propensity to prescribe, 66–69, 67f; empirical sequencing of use for users of, 62, 63f; instrumental variables regressions for, 70–73, 71t; physician propensity to prescribe, 66; relationship between relative price and use of, 72, 72f; robustness checks for analysis of, 73–75; sample selection for analyzing issues of, 59–60; simulations of reducing prescriber propensity for, 68t, 69; unconditional relationship between pain rate and propensity to prescribe, 69–70, 69f. *See also* hypertension drug treatments
- API (active pharmaceutical ingredients), 276
- Atkinson Review*, 44
- Augmentin XR, 266
- Australia, practices in volume measurement of health services in, 38t

- Austria, practices in volume measurement of health services in, 38t
authorized generics, 11
- Belgium, practices in volume measurement of health services in, 38t
- benefit incidence analysis, of public spending on health care, 462–70; ACA-relevant subgroups, 468–70, 469t; age groups, 464–66, 465t; aggregate results, 464, 465t; health status, 466, 467t; insurance coverage, 467t, 468; poverty level, 465t, 466. *See also* health care
- beta blockers, 58
- biomedical research, 475; assessing impact of, on cancer mortality, 486–90, 487–88t; kinds of evidence used by, 476; publications data for, 477–84; US spending on, 480–81, 481f
- BLS (Bureau of Labor Statistics) Industry Employment and Hours data, 149, 167
- body mass index (BMI), 8–10, 211
- brand name drugs, 275
- calcium channel blockers, 58
- Canada, practices in volume measurement of health services in, 38t
- cancer, 4, 56–57, 477; ARBs and, 56–58; assessing impact of biomedical research on mortality of, 486–90, 487–88t; correlation between sites of, between FY 2009 NIH funding and US government funded research publications, 482, 482f; descriptive statistics for incidence and mortality rates of, 490–94; econometric model of mortality rates of, 484–90; estimates of models of 1995–2009 growth of age-adjusted mortality rate of, 494–99, 501–2t; mortality rates of, 484–86; statistics used to assess progress in war on, 484; survival rates of, 484–85; types of statistics used to assess progress in war on, 484
- cancer incidence rate, defined, 477n2
- cancer medications, 12
- cardiology, disease-specific indexes for, 103–5, 104t
- case types, 46
- Center for Devices and Radiological Health (CDRH), 338
- Center for Drug Evaluation and Research (CDER), 338–40
- CER. *See* comparative effectiveness research (CER)
- CMS Statistical Supplement, 150, 166–67
- Code of Federal Regulations (CFR), 339–40
- COI. *See* cost-of-illness (COI) approaches; cost-of-illness (COI) studies
- commercial episode groupers, 184
- commercial grouper method, for MCEs, 119
- commercial health care market, 82
- comparative effectiveness research (CER), 3–4; about, 55; challenges to using observational data for, 63–64; conducting, 56
- comparative price levels (CPLs), 47, 48t; for health services, across countries, 48t
- conditions, medical: prevalence of, 123–29; ways of partitioning medical spending to, 7
- Consumer Price Index (CPI), medical services part of, 31
- contract manufacturing organizations (CMOs), 275, 276
- copayment incentive schemes, 255–56
- cost-of-illness (COI) approaches: all-encounter, 176; person level, 175–76; primary-encounter, 176
- cost-of-illness (COI) studies, 174; disease-based, 174; general, 174–75; literature review using all-encounter approach, 180–81, 182–83t; literature review using episode approach, 181–84; literature review using person-based approach, 184–86, 187t; literature review using person-based approach, methodological issues, 189–90t; literature review using primary-encounter approach, 176–77; literature review using primary-encounter method, 178–79t
- costs, medical. *See* health care costs
- course of treatment model, 6, 7, 148
- course of treatment model, of hospital output, 154–55
- Cozaar, 266
- CPI. *See* Consumer Price Index (CPI)
- CPLs. *See* comparative price levels (CPLs)
- Current Good Manufacturing Practice for Finished Pharmaceuticals (CGMP), 340
- Czech Republic, practices in volume measurement of health services in, 38t

- data sets, for calculating MCEs, 91–96, 119–29, 163–67; issues of treating prevalence of medical conditions in, 123–29; Medical Current Beneficiary Survey (MCBS), 119–21; Medical Expenditure Panel Survey (MEPS), 120t, 121–23; Medicare claims, 120t, 121; Medicare Current Beneficiary Survey (MCBS), 120t
- Denmark, practices in volume measurement of health services in, 38t
- diagnosis-related groups (DRGs), 6, 164n28, 170
- disease-specific indexes, 103–9, 174; cardiology, 103–5, 104t; endocrinology, 103–5, 104t; gastroenterology, 105, 106t; gynecology, 105–7, 108t; neoplasms, 107, 109. *See also* medical care expenditure indexes (MCEs)
- diuretics, 58
- DRGs. *See* diagnosis-related groups (DRGs)
- drugs. *See* brand name drugs; generic pharmaceuticals; infused/injected drugs; injectable drugs, shortages of; loss of exclusivity (LOE); noninjectable drugs, shortages of; specialty drugs
- drug shortages, 323–24; age of unresolved, 325; causes of, 13–14; data used for study of, 335–38; generic drugs and, 13; information on FDA regulatory activity for study of, 338–42; institutional character of US generic market and, 328–30; modeling and analysis for, 342–45; patterns in average, 323–25, 324f; predicting, as result of LOE, 301–3; prices and, 333–34; regression models of, 346–47; regulatory involvement and, 330–33; for selected noninjectable, 326–27, 326t; starts, 325f
- Einav-Finkelstein (EF) model, of adverse selection, 380; literature review of, 382–86
- employer-sponsored insurance, data and study sample, 188–92
- encounter-based allocations, 194
- encounter-level costing, 174–75
- endocrinology, disease-specific indexes for, 103–5, 104t
- episode-based approach, to COI allocation, 181–82
- ETG Symmetry grouper, 92, 92n12
- European System of Accounts (ESA 1995), economic significance of prices and, 28–29
- exclusivity, loss of. *See* loss of exclusivity (LOE)
- extended units (EUs) per prescriptions, 255–56
- fee-for-service (FFS) Medicare, 114, 124
- Finland, practices in volume measurement of health services in, 38t
- France, practices in volume measurement of health services in, 39t
- gastroenterology, disease-specific indexes for, 105, 106t
- general COI studies, 174–75
- Generic Drug User Fee Act, 332
- generic pharmaceuticals, 275; authorized, 11; cancer medications and, 12; causes of, 13–14; findings on characteristics of six initial launches of, 247–48, 249t; loss of patient exclusivity and prices of, 12; market share of, conclusions about, 263–66; overall penetration rates of, by payer type and age, 250–53, 251t; penetration rates of, overall and by payer type and age, 11, 250–53, 251t; quantities post-LOE relative to pre-LOE, 253–55, 254t; results of study of, 248–50; shortages and, 13. *See also* loss of exclusivity (LOE); specialty drugs
- Germany, practices in volume measurement of health services in, 39t
- Greece, practices in volume measurement of health services in, 39t
- Hatch-Waxman Act, 244
- health accounting, 1
- health care: aggregate public spending on, 460–62; benefit incidence of public spending on, 462–70, 465t; institutions and provision of, in OECD countries, 29–30; limitations of study of, 470–71; per capita public and private spending on, 1960–2012, 461f; public spending on, 20–21; spending on, in US, 459; volume measurement of, 30–36. *See also* benefit incidence analysis

- health care costs: current state of, 2; data issues concerning, 3; econometric approach for modeling, 175; growth in, 173; health benefits and, 21; industrial organization of medical care and, 15–16; obesity and (*see* obesity); results of study sample of diseases, 195–200; valuing nonmarket activities, 2–3
- health care expenditures. *See* medical care expenditures
- health care sector, measuring inflation in, 113
- health insurance markets, 16
- health services: comparisons of price levels and volumes of, 43–49; domestic demand for, 25; history of measuring, 27; over of country practices in volume measurement of, 37–43, 38–41t; variations in domestic demand for, in OECD countries, 25–27, 27f; volume measurement of, 30–31
- Herfindahl-Hirschman Indexes (HHIs), 16, 361–70; for individual markets, 2010, 439f; for individual markets, 2012, 440f; for individual/small group markets, 18–19; for small group markets, 2010, 440f
- hospital industry: changes in, 146; characteristics of, that present challenges of measuring output of, 158–59; creating output index for, 146–49; as sector in US economy, 145. *See also* private hospitals
- hospital outputs: course of treatment model of, 151–54; course of treatment model of, results for, 159–61, 160f; data sources for creating models of, 149–51, 151t; ideal measure of, 148–49; primary methods of measuring, 149; procedures model of, 155–57; procedures model of, results for, 161; revenue model of, 157–59; revenue model of, results for, 162; review of course of treatment model of, 154–55. *See also* outcomes; private hospitals
- hospital services: defining, based on outcome of treatment, 148; inpatient, 147–48, 147f; outpatient, 147, 147f
- hypertension: adherence of initial treatment by drug class for, 60–61, 61t; ARBs and, 56; defined, 57–58; drug classes, 58; drugs used for treating, 58. *See also* angiotensin II receptor blockers (ARBs)
- hypertension drug treatments: incident cases, 60; incident cases, descriptive statistics for, 63, 65t; left censoring and, 60; prevalent cases, 59–60; prevalent cases, descriptive statistics for, 63, 64t. *See also* angiotensin II receptor blockers (ARBs)
- Iceland, practices in volume measurement of health services in, 39t
- incremental cost, of health plans, 382
- indexes. *See* medical care expenditure indexes (MCEs)
- individual markets: distribution of premiums in, 449f; enrollment and market share by type of insurer in, 432–33t; entry and exit of insurers in, 2010–2012, 438t; evaluating insurer performance prior to 2010 in, 442–44; evaluating insurer performance 2010 and after in, 444–53; HHI for, 2010, 439f; HHI for, 2012, 440f; MLRs for fully credible insurers in, 2010–2012, 451t; number of insurers selling comprehensive health insurance in, 430–31t; performance of insurers in, for health insurance, 442–53; premiums and claims in, 447f; size of, 421–24; structure of, for health insurance, 425–27; structure of, for health insurance, in 2010 and after, 428–42; structure of, for health insurance, prior to 2010, 427–28. *See also* small group markets
- individual/small group markets, 18–19; coverage information and estimates by survey, 2009, 423t; size of, 421–25
- industrial organization (IO), of medical care, medical costs and, 15–16
- inflation, in health care sector, measuring, 113
- infused/injected drugs: barriers to entry for manufacturing, 276; manufacturers of, as contract manufacturers, 276–77; manufacturing technology for, 276
- injectable drugs, shortages of, 12–13; empirical analyses of, 14–15
- inpatient index, adjusting, for survival rates, 170–72

- inpatient services, 147–48, 147f
- insurance coverage, population distribution of, in US, 188, 191f. *See also* employer-sponsored insurance
- insurance market structure: in 2010 and after, 428–42; prior to 2010, 427–28
- International Classification of Diseases, Ninth Revision, Clinical Modifications (ICD-9-CM), 150, 150n16
- Ireland, practices in volume measurement of health services in, 39t
- Italy, practices in volume measurement of health services in, 39t
- Japan, practices in volume measurement of health services in, 39t
- knowledge, counts of publications as indicators of, 477
- Korea, practices in volume measurement of health services in, 39t
- labor productivity, hospital, 159, 160f
- left censoring, 60
- Lexapro, 267–68
- Lipitor, 267
- loss of exclusivity (LOE), of prescription drugs, 12, 243–45, 273–74; data and methodology for analyses of, 246–47; findings of analyses of, 245–46; policy implications of, 304–10; predicting shortages as a result, results of, 301–3; quantities post- relative to pre-, 253–55, 254t; results of count models for, 290–94; results of impact of, on utilization volume, 298–301; results of supplier prices following, 294–98; robustness of findings for, 304. *See also* generic pharmaceuticals; specialty drugs
- Luxembourg, practices in volume measurement of health services in, 40t
- MarketScan database, 91, 188; variables in, 193t
- MCEs. *See* medical care expenditure indexes (MCEs)
- medical care. *See* health care
- medical care costs. *See* health care costs
- medical care expenditure indexes (MCEs), 4–6, 115; central problem in creation of, 116; commercial grouper software for, 119; comparison of, based on calculations from different data sets, 137–39; comparisons of different methods for calculating, 130–37; data sets for calculating (*see* data sets, for calculating MCEs); effect of adjustment to growth rate on, for all Medicare beneficiaries, 129, 129t; methodology of construction of, 85–90; primary diagnosis method for, 118–19; regression-based method for, 116–18; results of study of, 96–109. *See also* disease-specific indexes
- medical care expenditures: aggregated indexes for, 96–98; data sources for, 91–96; disease-specific indexes, 103–9; domestic, as percentage of GDP, 26–27, 27f; largest contributors to growth in, 83–85; major practice categories for, 98–103, 100t; methodology of index construction for, 85–91; sources of, 83; three largest contributors to growth in, 83–84; total, equation for, 123; in US, 81, 459
- medical care spending, decomposition of, 5
- Medical Expenditure Panel Study (MEPS), 9, 17, 18, 20, 121–23, 390, 462–64; constructing outpatient index and, 167–70; critique of, 168–69; prevalence by year in, 127–28t; for study of obesity, 220–21; treated prevalence in, 126–29, 127–28t. *See also* medical care expenditure indexes (MCEs)
- Medical Expenditure Panel Survey (MEPS), Household Component of, 114
- medical innovation, benefits of, 21
- medical loss ratios (MLRs), 17–20, 420; for fully credible insurers in individual markets, 2010–2012, 451t; for fully credible insurers in small group markets, 2010–2012, 451t; in individual markets prior to 2010, 442–44; in individual markets 2010 and after, 444–53; for partially credible insurers in individual markets, 2010–2012, 452t; for partially credible insurers in small group markets, 2010–2012, 452t; in small group markets prior to 2010, 442–44; in small group markets 2010 and after, 444–53
- medical loss ratios (MLRs) regulations, 420–21

- medical research. *See* biomedical research
- Medical Subject Headings (MeSH), 478, 478n4
- Medicare claims data, 354–55
- Medicare Current Beneficiary Survey (MCBS), 11, 119–21; treated prevalence in, 123–26, 125t. *See also* medical care expenditure indexes (MCEs)
- Medicare program, 114; data sets for, 114
- Medline, 478
- MEPS. *See* Medical Expenditure Panel Study (MEPS)
- MLRs. *See* medical loss ratios (MLRs)
- mortality rates, 484–86. *See also* cancer
- National Hospital Ambulatory Medical Care Survey (NHAMCS), 150, 165–66
- National Prescription Audit (NPA) data, 246
- National Provider Identifiers (NPIs), 356–57, 358t
- National Sales Perspectives (NSP) data, 286
- Nationwide Inpatient Sample (NIS), 149–51, 150n13, 163–65, 164n27
- neoplasms, disease-specific indexes for, 107, 109
- Netherlands, practices in volume measurement of health services in the, 40t
- New Zealand, practices in volume measurement of health services in, 40t
- ninety-day prescriptions, 255–56
- NIS (Nationwide Inpatient Sample). *See* Nationwide Inpatient Sample (NIS)
- noninjectable drugs, shortages of, 12–13; empirical analyses of, 14–15
- nonmarket activities, valuing, 2–3
- Norway, practices in volume measurement of health services in, 41t
- NPA (National Prescription Audit) data, 246
- NPIs (National Provider Identifiers), 356–57, 358t
- NSP (National Sales Perspectives) data, 286
- obesity: data used for study of, 220–24; estimating equations for, 224–26; explaining, through use of behavioral economics, 212; health care costs and, 211–12; life-expectancy loss and, 211; rates of, 212; results of study of, 226–34; simple micromodel of, 215–20; simulations for, 234–36; studies of, 8; study of, explained, 212–15; summary statistics for study of, 221–24, 223–24t; US rate of, 221, 221f
- observation data, challenges to using, for CER, 63–66
- OECD countries. *See* Organisation for Economic Co-operation and Development (OECD) countries
- 180-day triopolies, 259–60
- optimal risk adjustment, 16–17
- Organisation for Economic Co-operation and Development (OECD) countries: overview of practices in, 37–43, 38–41f; variations in domestic demand for health services in, 25–27, 27f
- outcomes: meanings of, 37; volume measurement of health services and, 31–33
- outpatient services, 147, 147f
- outputs, volume measurement of health services and, 31–33. *See also* hospital outputs
- patient exclusivity, loss of, specialty markets and, 12
- person approach, to COI allocation, 176, 194–95; estimation techniques in, 186–88; literature review using, 184–86, 187t
- person-based allocations, 194–95
- person-level costing, 175
- pharmaceutical markets: generic drugs and, 11; prescription, 10–15; special markets and, 11–12; specialty drugs and, 11–12
- physician market structure, understanding impact of changes in, 352
- physician practices: about, 351–53; area-level analyses of, 369–70; concentration measurers for (*see* Herfindahl-Hirschman Indexes [HHIs]); identifying, with TINs, 355–56; Medicare claims data for, 354–55; methods of organizing, 353–54; SK&A (consulting firm) data for, 370–74; studying concentration of, with HHIs, 361–69; trends in number and size of, 358–60, 361t
- physicians: identifying, with NPIs, 356–57, 358t; percentage of, *see* Medicare patients, 357
- Plavix, 268
- Portugal, practices in volume measurement of health services in, 41t

- prescription drugs: cash vs. full sample
 average price levels and growth rates
 of, 261–63; extending, to ninety-days,
 255–56; findings of LOE and, 245–46;
 loss of exclusivity (LOE) and, 243–45;
 price per day of therapy by payer type,
 256–59; prices and prescription shares
 during 180-day triopoly, 259–60; prices
 per day of therapy by payer type, 257;
 shortages and, 278; supply and demand
 side prices of, 278–81; types of, 275
- price per day of therapy by payer type,
 256–59, 257f
- primary diagnosis method, for MCEs,
 118–19
- primary-encounter approach, to COI allo-
 cation, 176; literature review, 176–77,
 178–79t
- private hospitals, 146; labor productivity
 in, 159, 160f, 161f; measuring out and
 productivity growth in, 6–7; output for,
 159f. *See also* hospital outputs
- procedures model, of hospital output, 6,
 155–57
- Producer Price Indexes (PPIs), 6, 151, 167
- publications: correlation between
 major cancers and number of US
 government-funded, 481–82, 482f;
 counts of, as indicators of knowledge,
 477; distribution of NIH-supported, by
 lag between start date and publication
 date, 483–84, 483f
- public spending, on medical care, 20–21
- PubMed, 477–78, 478n3; abridge sample of
 bibliographic citations of, 479t; number
 of publications pertaining to cancer,
 478–81, 480f
- purchasing power parity (PPP), health-
 specific, 45–46
- Qualified Health Plans (QHPs), 393
- quality adjustments, components of, 44–45,
 44f
- quality changes in products, dealing with
 health services, 35–36
- quasi prices, 46–47
- randomized controlled trials (RCTs), 55;
 compared to IV regressions, 75–76;
 contamination bias and, 60–63
- regression-based method, for MCEs, 116–18
- revenue model, 6
- risk adjustment: adverse selection and, 379–
 80; empirical application for, 390–98; to
 fix adverse selection, 386–90; limits of
 methods for formulas of, 380; results of
 empirical application for, 398–410
- Service Annual Survey (SAS), 151
- SHCE (Supplemental Health Care Exhibit),
 427, 453
- shortages. *See* drug shortages; injectable
 drugs, shortages of; noninjectable
 drugs, shortages of
- shortages, of injectable and noninjectable
 drugs, 12–13; empirical analysis of,
 14–15
- SK&A (consulting firm) data, for physician
 practices, 370–74
- Small Business Health Options Program
 (SHOP) exchanges, 419–20, 420n2
- small group markets: distribution of premi-
 ums in, 449f; enrollment and market
 share by type of insurer in, 436–37t;
 entry and exit of insurers in, 2010–
 2012, 438t; estimates of employees
 with health insurance coverage, 425t;
 evaluating insurer performance prior
 to 2010 in, 442–44; evaluating insurer
 performance 2010 and after in, 444–53;
 HHI for, 2010, 440f; HHI for, 2012,
 441; MLRs for fully credible insurers
 in, 2010–2012, 451t; number of insurers
 selling comprehensive health insurance
 in, 434–35t; performance of insurers in,
 for health insurance, 442–53; premiums
 and claims in, 448f; size of, 421–25;
 structure of, for health insurance, 425–
 42; structure of, for health insurance, in
 2010 and after, 428–42; structure of, for
 health insurance, prior to 2010, 427–28.
See also individual markets
- SNA. *See* System of National Accounts
 (SNA 2008)
- specialty drugs, 11–12; data and descrip-
 tive trends for, 286–90; institutions
 governing entry, manufacturing, and
 pricing of, 275–81; loss of patient
 exclusivity of, 12; policy implications of
 analyses of, 304–10; results of analyses,
 290–304; theoretical considerations and
 empirical findings for entry models of,
 281–86. *See also* generic pharmaceuti-
 cals; loss of exclusivity (LOE)

- stroke, 4, 45
- Supplemental Health Care Exhibit (SHCE), 427, 453
- survival rates, 484–85. *See also* cancer
- Sweden, practices in volume measurement of health services in, 41t
- Switzerland, practices in volume measurement of health services in, 41t
- symmetry grouper, 91–92; ETG, 92, 92n12
- System of National Accounts (SNA 2008), 27–28; current price measures of, 28–30
- Tax Identification Numbers (TINs), 15–16, 354–55; identifying physician practices with, 355–56
- TAXSIM model, 20–21, 463, 463n5
- TINs. *See* Tax Identification Numbers (TINs)
- total healthcare spending, equation for, 123
- triopoly period, 259–60; defined, 11
- 2008 System of National Accounts (SNA 2008), 27; complications in health provision measurement in, 29–30; distinction between inputs, outputs, and outcomes of, 31–33; economic significance of prices and, 28–29; volume measurement of health services and, 30–31
- United Kingdom: explicit quality adjustments in, 44–45; practices in volume measurement of health services in, 41t
- United States: health care spending in, 459; insurance coverage in, 188, 191f; medical care expenditures per capita in, 81; obesity rate of, 221, 221f; practices in volume measurement of health services in, 41t; spending on biomedical research by, 480–81, 481f
- vasodilators, 58
- volume measurement, of health services: market/nonmarket producers and, 30–31; outputs and outcomes of, 31–33; quality change and, 35–36; weights and, 33–35
- weights, choice of aggregation for types of outputs and, 33–35